These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28977629)

  • 1. The cost-effectiveness of public health interventions examined by NICE from 2011 to 2016.
    Owen L; Pennington B; Fischer A; Jeong K
    J Public Health (Oxf); 2018 Sep; 40(3):557-566. PubMed ID: 28977629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of public health interventions examined by the National Institute for Health and Care Excellence from 2005 to 2018.
    Owen L; Fischer A
    Public Health; 2019 Apr; 169():151-162. PubMed ID: 30885422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of public health interventions.
    Owen L; Morgan A; Fischer A; Ellis S; Hoy A; Kelly MP
    J Public Health (Oxf); 2012 Mar; 34(1):37-45. PubMed ID: 21933796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary health care economics: an overview.
    McLaughlin N; Ong MK; Tabbush V; Hagigi F; Martin NA
    Neurosurg Focus; 2014 Nov; 37(5):E2. PubMed ID: 25363430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis in minimally invasive spine surgery.
    Al-Khouja LT; Baron EM; Johnson JP; Kim TT; Drazin D
    Neurosurg Focus; 2014 Jun; 36(6):E4. PubMed ID: 24881636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discounting in cost-utility analysis of healthcare interventions: reassessing current practice.
    Cohen BJ
    Pharmacoeconomics; 2003; 21(2):75-87. PubMed ID: 12515570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Benefit Analysis versus Cost-Effectiveness Analysis from a Societal Perspective in Healthcare.
    Brent RJ
    Int J Environ Res Public Health; 2023 Mar; 20(5):. PubMed ID: 36901658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of economic evaluation on quality management in spine surgery.
    Boos N
    Eur Spine J; 2009 Aug; 18 Suppl 3(Suppl 3):338-47. PubMed ID: 19337760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk.
    Fairbairn TA; Meads DM; Hulme C; Mather AN; Plein S; Blackman DJ; Greenwood JP
    Heart; 2013 Jul; 99(13):914-20. PubMed ID: 23696198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying economic evaluation to public health interventions: the case of interventions to promote physical activity.
    Trueman P; Anokye NK
    J Public Health (Oxf); 2013 Mar; 35(1):32-9. PubMed ID: 22753453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluations of public health implementation-interventions: a systematic review and guideline for practice.
    Reeves P; Edmunds K; Searles A; Wiggers J
    Public Health; 2019 Apr; 169():101-113. PubMed ID: 30877961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analyses in spine care: a qualitative and systematic review.
    Nwachukwu BU; Schairer WW; Shifflett GD; Kellner DB; Sama AA
    Spine (Phila Pa 1976); 2015 Jan; 40(1):31-40. PubMed ID: 25341977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?
    Culyer AJ; Chalkidou K
    Value Health; 2019 Jan; 22(1):99-103. PubMed ID: 30661640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the cost-effectiveness of pay-for-performance in primary care in the UK.
    Pandya A; Doran T; Zhu J; Walker S; Arntson E; Ryan AM
    BMC Med; 2018 Aug; 16(1):135. PubMed ID: 30153827
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.